Latest news and press releases about Onconetix, Inc. (ONCO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH).
Price
| Price | $0.66 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.11 |
| EV / EBITDA | 0.21 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -91.95% |
| Return on Invested Capital | -59.84% |
| Return on Assets | -62.07% |
| Gross Margin | 80.40% |
| Operating Margin | -1265.55% |
| Net Margin | -1578.79% |
Related companies: AZTR · ENVB · INDP · JSPR · PTIX · REVB · SCNI
Explore sector: Healthcare · Biotechnology
More sections of ONCO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks